iTeos Therapeutics Price Target Lowered to 19.00 at Wells Fargo Company
| ITOS Stock | USD 7.76 0.05 0.64% |
Slightly above 62% of Iteos Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Iteos Therapeutics suggests that many traders are alarmed. Iteos Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Iteos Therapeutics' earnings reports, geopolitical events, and overall market trends.
Iteos |
iTeos Therapeutics had its price target reduced by Wells Fargo Company from 31.00 to 19.00 in a research report sent to investors on Thursday morning,Benzinga reports. Wells Fargo Company currently has an overweight rating on the stock. A number of other brokerages have also issued reports on ITOS. Wedbush
Read at thelincolnianonline.com
 |
Iteos Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Iteos Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Iteos Therapeutics Fundamental Analysis
We analyze Iteos Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Iteos Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Iteos Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Beta
Beta Comparative Analysis
Iteos Therapeutics is currently under evaluation in beta category among its peers. Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Iteos Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Iteos Therapeutics stock to make a market-neutral strategy. Peer analysis of Iteos Therapeutics could also be used in its relative valuation, which is a method of valuing Iteos Therapeutics by comparing valuation metrics with similar companies.
Peers
Iteos Therapeutics Related Equities
| ANNX | Annexon | 0.21 |
| ||
| TCRX | Tscan Therapeutics | 2.81 |
| ||
| ABOS | Acumen Pharmaceuticals | 2.94 |
| ||
| DAWN | Day One | 3.28 |
| ||
| BPMC | Blueprint Medicines | 3.53 |
| ||
| MLTX | MoonLake Immunotherapeuti | 3.84 |
| ||
| TERN | Terns Pharmaceuticals | 4.57 |
| ||
| GLUE | Monte Rosa | 4.84 |
| ||
| KYMR | Kymera Therapeutics | 5.80 |
| ||
| RVMD | Revolution Medicines | 5.94 |
| ||
| AMLX | Amylyx Pharmaceuticals | 7.16 |
| ||
| DSGN | Design Therapeutics | 11.02 |
| ||
| ERAS | Erasca | 13.82 |
| ||
| SANA | Sana Biotechnology | 14.88 |
| ||
| APLS | Apellis Pharmaceuticals | 16.85 |
|
Additional Tools for Iteos Stock Analysis
When running Iteos Therapeutics' price analysis, check to measure Iteos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Iteos Therapeutics is operating at the current time. Most of Iteos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Iteos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Iteos Therapeutics' price. Additionally, you may evaluate how the addition of Iteos Therapeutics to your portfolios can decrease your overall portfolio volatility.